{
    "clinical_study": {
        "@rank": "92668", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability of single and multiple\n      doses of intramuscular INGAP Peptide given for the first time in humans as a potential\n      treatment for diabetes."
        }, 
        "brief_title": "Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients", 
        "condition": [
            "Diabetes Mellitus, Type 1", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients meeting all of the following inclusion criteria at screening can be considered\n        for admission to the study.\n\n        Stage 1 and Stage 2:\n\n          1. Male and female patients with, type 1 diabetes mellitus that are 18 through 70 years\n             of age, or type 2 diabetes mellitus that are 30 through 70 years of age.\n\n          2. Patients who are insulin deficient and are diagnosed with type 1 or type 2 diabetes\n             mellitus, and are currently well managed with insulin, with or without metformin.\n\n          3. Patients who have been on stable doses of insulin treatment for 90 days prior to\n             study randomization.\n\n        Exclusion Criteria:\n\n        Patients meeting any of the following exclusion criteria at screening will not be enrolled\n        in the study:\n\n          1. Patients with a history of any clinically significant retinopathy, symptomatic\n             autonomic neuropathy, unstable angina, or kidney problems.\n\n          2. Patients with an uncontrolled or untreated significant pulmonary, neurological\n             condition, or cardiovascular disease, including hypertension, congestive heart\n             failure, angina, or peripheral vascular disease.\n\n          3. Patients who have received any investigational product within 30 days of admission\n             into the study.\n\n          4. Patients with a history or clinical evidence of multiple organ autoimmune disorders.\n\n          5. Patients with a medical condition, serious intercurrent illness, or extenuating\n             circumstance that would significantly decrease study compliance, including all\n             prescribed follow-up.\n\n          6. Patients who are lactating and breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "62", 
        "firstreceived_date": "April 24, 2002", 
        "id_info": {
            "nct_id": "NCT00034255", 
            "org_study_id": "INGAP-01-001"
        }, 
        "intervention": {
            "intervention_name": "INGAP Peptide", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92161"
                    }, 
                    "name": "VASDHS Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20003"
                    }, 
                    "name": "MedStar Research Institute - Clinical Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27713"
                    }, 
                    "name": "UNC Diabetes, Endocrinology, Metabolism Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78284"
                    }, 
                    "name": "Texas Diabetes Institute"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00034255"
        }, 
        "source": "GMP Endotherapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GMP Endotherapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2003"
    }, 
    "geocoordinates": {
        "MedStar Research Institute - Clinical Research Center": "38.895 -77.036", 
        "Texas Diabetes Institute": "29.424 -98.494", 
        "UNC Diabetes, Endocrinology, Metabolism Clinic": "35.994 -78.899", 
        "VASDHS Medical Center": "32.715 -117.157"
    }
}